Editing Transdermal patch (section)

== Adverse events ==
*In 2005, the [[U.S. Food and Drug Administration|FDA]] announced that they were investigating reports of death and other serious adverse events related to [[narcotic]] [[overdose]] in patients using [[Duragesic]], the [[fentanyl]] transdermal patch for pain control. The Duragesic product label was subsequently updated to add safety information in June 2005.<ref>{{cite web | url = https://www.fda.gov/cder/drug/InfoSheets/HCP/fentanylHCP.htm | title = FDA ALERT (07/2005): Narcotic Overdose and Death | publisher = [[Food and Drug Administration]] | date = 2005-07-15 |access-date = 2007-02-24 |archive-url = https://web.archive.org/web/20070220083526/https://www.fda.gov/cder/drug/InfoSheets/HCP/fentanylHCP.htm <!-- Bot retrieved archive --> |archive-date = 2007-02-20}}</ref> <!--- NOTE TO THE EDITORS: It should be added here that these overdoses were usually accomplished by combining Fentanyl patches with a drug called Cisapride, which is no longer available on the US market due to cardiac arrythmias. Or, they boiled the patches to extract the drug which is also no longer an option. Need source though. -->
*In 2007, Shire and Noven Pharmaceuticals, manufacturers of the [[Daytrana]] ADHD patch, announced a voluntary recall of several lots of the patch due to problems with separating the patch from its protective release liner.<ref name="DaytranaRecall">{{cite web|url=http://www.in-pharmatechnologist.com/Materials-Formulation/ADHD-transdermal-patches-withdrawn|title=ADHD Transdermal Patches Withdrawn|date=2007-09-05|access-date=2010-09-28|author=Megget, Katrina}}</ref> Since then, no further problems with either the patch or its protective packaging have been reported.
*In 2008, two manufacturers of the fentanyl patch, ALZA Pharmaceuticals (a division of major medical manufacturer [[Johnson & Johnson]]) and [[Sandoz]], subsequently issued a recall of their versions of the patch due to a manufacturing defect that allowed the gel containing the medication to leak out of its pouch too quickly, which could result in overdose and death.<ref name="PatchRecall">{{cite web|url=http://www.pharmalot.com/2008/02/jj-and-sandoz-recall-fentanyl-patches/|title=J&J and Sandoz Recall Fentanyl Patches|date=2008-02-12|access-date=2010-09-28|author=Silverman, Ed}}</ref> As of March 2009, Sandoz—now manufactured by ALZA—no longer uses gel in its transdermal fentanyl patch; instead, Sandoz-branded fentanyl patches use a matrix/adhesive suspension (where the medication is blended with the adhesive instead of held in a separate pouch with a porous membrane), similar to other fentanyl patch manufacturers such as Mylan and Janssen.<ref name="SandozPackaging">As stated on the packaging and labels of Sandoz-branded Fentanyl Transdermal System products, revised March 2009.</ref>
*In 2009, the FDA announced a public health advisory warning of the risk of burns during [[Magnetic resonance imaging|MRI]] scans from transdermal drug patches with metallic backings. Patients should be advised to remove any medicated patch prior to an MRI scan and replace it with a new patch after the scan is complete.<ref>{{cite web|url=https://www.fda.gov/cder/drug/advisory/transdermalpatch.htm |title=FDA Public Health Advisory: Risk of Burns during MRI Scans from Transdermal Drug Patches with Metallic Backings |website=[[Food and Drug Administration]] |access-date=March 9, 2009 |archive-url=https://web.archive.org/web/20090307042455/https://www.fda.gov/cder/drug/advisory/transdermalpatch.htm |archive-date=March 7, 2009 }}</ref>
*In 2009, an article in ''Europace'' journal detailed stories of skin burns that occurred with transdermal patches that contain metal (usually as a backing material) caused by shock therapy from external as well as internal cardioverter [[defibrillators]] (ICD).<ref name="Europace">Brown, MR: "Analgesic patches and defibrillators: a cautionary tale", ''Europace'',2009 Nov;11(11):1552-3</ref>